Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a post on LinkedIn:
“A major step forward for precision oncology.
I am pleased to share that Reveal Genomics has signed a strategic agreement with Avançsa, the public financial instrument of the Government of Catalonia (Generalitat de Catalunya) dedicated to supporting industrial growth, innovation, and high-impact companies.
Through this agreement, Avançsa will provide €2M in participative financing, enabling Reveal Genomics to:
- Advance the CE-IVDR process for our HER2DX test and strengthen our regulatory and manufacturing capabilities.
- Accelerate our international expansion across Europe, North America, and Asia.
- Contribute to the growth of the biotech sector in Catalonia by creating high-skilled jobs and reinforcing a strong innovation ecosystem.
For a spin-off founded in 2020 with the mission of bringing precision oncology tools to clinical practice, this partnership marks an important inflection point.
A big thank you to Avançsa for their trust and commitment, and congratulations to the entire Reveal Genomics team for making this possible.
Onward.”
More posts featuring Aleix Prat.
